文献速递冠心病外科

缺血性心肌病中优化药物治疗联合或不联合外科血运重建的长期结局

Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-01-07

基于STICH试验1212例冠脉病变且左室射血分数≤35%患者,比较CABG联合药物与单纯药物治疗,中位随访9.8年。基线与4个月优化药物治疗比例分别为58.7%和73.3%,优化药物治疗与更低全因死亡率相关,且与治疗分配无交互作用。

要点

  • 缺血性心肌病患者中优化药物治疗与更低全因死亡率相关。
  • 优化药物治疗的获益与是否行CABG无交互作用。
  • 应强烈推荐缺血性心肌病患者接受优化药物治疗。

核心结论

  • 优化药物治疗与缺血性心肌病患者长期生存改善和心血管死亡率降低相关,应强烈推荐。

研究设计与样本

  • STICH试验随机1212例冠脉病变且左室射血分数≤35%患者至CABG联合药物治疗或单纯药物治疗,中位随访超过9.8年。
  • 优化药物治疗在基线和4个月时收集,定义为ACEI或ARB、β受体阻滞剂、他汀和1种抗血小板药的组合。

主要发现

  • 基线和4个月时分别有58.7%和73.3%患者接受优化药物治疗。
  • 多变量Cox模型中,基线优化药物治疗与更低全因死亡率相关(HR 0.78;95%CI 0.66-0.91;P=.001)。
  • 以4个月为界标时,优化药物治疗也与更低全因死亡率相关(HR 0.82;95%CI 0.62-0.99;P=.04)。
  • 优化药物治疗的获益与治疗分配之间无交互作用。

临床怎么用

  • 对缺血性心肌病患者应强烈推荐优化药物治疗,无论是否行CABG。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Optimal medical therapy in patients with heart failure and coronary artery disease is associated with improved outcomes. However, whether this association is influenced by the performance of coronary artery bypass grafting is less well established. Thus, the aim of this study was to determine the possible relationship between coronary artery bypass grafting and optimal medical therapy and its effect on the outcomes of patients with ischemic cardiomyopathy. METHODS: The Surgical Treatment for Ischemic Heart Failure trial randomized 1212 patients with coronary artery disease and left ventricular ejection fraction 35% or less to coronary artery bypass grafting with medical therapy or medical therapy alone with a median follow-up over 9.8 years. For the purpose of this study, optimal medical therapy was collected at baseline and 4 months, and defined as the combination of 4 drugs: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, statin, and 1 antiplatelet drug. RESULTS: At baseline and 4 months, 58.7% and 73.3% of patients were receiving optimal medical therapy, respectively. These patients had no differences in important parameters such as left ventricular ejection fraction and left ventricular volumes. In a multivariable Cox model, optimal medical therapy at baseline was associated with a lower all-cause mortality (hazard ratio, 0.78; 95% confidence interval, 0.66-0.91; P = .001). When landmarked at 4 months, optimal medical therapy was also associated with a lower all-cause mortality (hazard ratio, 0.82; 95% confidence interval, 0.62-0.99; P = .04). There was no interaction between the benefit of optimal medical therapy and treatment allocation. CONCLUSIONS: Optimal medical therapy was associated with improved long-term survival and lower cardiovascular mortality in patients with ischemic cardiomyopathy and should be strongly recommended.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Farsky PS, White J, Al-Khalidi HR, et al. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy. J Thorac Cardiovasc Surg. 2021. PMID: 33610365. doi:10.1016/j.jtcvs.2020.12.094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。